Oppenheimer raised the firm’s price target on Prothena (PRTA) to $62 from $58 and keeps an Outperform rating on the shares. The firm sees a ...

A Cavan woman battling a rare and incurable form of bone marrow cancer hopes to run her 600th lifetime marathon by June of this year.

Mayo Clinic recently announced separate generative artificial intelligence collaborations with Microsoft Research and ...